Managing post-transplant lymphoproliferative disorders in solid-organ transplant recipients: A review of immunosuppressant regimens

Drugs

Volumn 72, Issue 12, 2012, Pages 1631-1643

  Murukesan, Vidhya ^a   Mukherjee, Sandeep ^b  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b Division of Gastroenterology and Hepatology   (United States)

Author keywords

Bone marrow transplant; Epstein Barr virus infections; Immunosuppression; Organ transplant; Post transplant lymphoproliferative disorder

Indexed keywords

ACICLOVIR; AZATHIOPRINE; BASILIXIMAB; BETALACEPT; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; DOXORUBICIN; EPSTEIN BARR VIRUS VACCINE; EVEROLIMUS; GALECTIN 1 MONOCLONAL ANTIBODY; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; INTERLEUKIN 6 ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; TEMSIROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VINCRISTINE;

ADOPTIVE IMMUNOTHERAPY; AGE; B CELL LYMPHOMA; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CLINICAL TRIAL (TOPIC); CYTOMEGALOVIRUS INFECTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MANTLE CELL LYMPHOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; ORGAN TRANSPLANTATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PROTEIN EXPRESSION; RADIATION DOSE; RADIOTHERAPY; RECURRENCE RISK; REVIEW; RISK FACTOR; SIDE EFFECT; SKIN CANCER; SURVIVAL RATE; SURVIVAL TIME; VIRUS REACTIVATION;

CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOPROLIFERATIVE DISORDERS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TRANSPLANTS;

HUMAN HERPESVIRUS 4; MAMMALIA;

EID: 84864654874     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11635690-000000000-00000     Document Type: Review

References (109)

1. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984 Mar; 1 (8377): 583-7 (Pubitemid 14156511)
2. Vegso G, Hajdu M, Sebestyen A. Lymphoproliferative disorders after solid organ transplantation-classification, incidence, risk factors, early detection and treatment op-tions. Pathol Oncol Res 2011 Sep; 17 (3): 443-54
3. Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995 Apr; 13 (4): 961-8
4. Allen U, Hebert D, Moore D, et al. Epstein-Barr virus- related post-transplant lymphoproliferative disease in solid organ transplant recipients, 1988-97: a Canadian multi-centre experience. Canadian PTLD Survey Group -1998. Pediatr Transplant2001 Jun; 5 (3): 198-203 (Pubitemid 32545267)
5. Mucha K, Foroncewicz B, Ziarkiewicz-Wroblewska B, et al. Post-transplant lymphoproliferaive disorder in view of the new WHO classification: a more rational approach to a protean disease? Nephrol Dial Translant 2010; 25: 2089-98
6. Allen U, Preiksaitis J. Epstein-Barr virus and post- transplant lymphoproliferative disorder in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl. 4: S87-96
7. McLaughlin K, Wajstaub S, Marotta P, et al. Increased risk for posttransplant lymphoproliferative disease in re-cipients ofliver transplants with hepatitis C. Liver Transpl 2000; 6: 570-4
8. Opelz G, Dohler B. Lymphomas after solid organ trans- plantation: a collaborative transplant study report. Am J Transplant 2003; 4: 222-30
9. Opelz G, Dohler B. Impact of HLA mismatching on in- cidence of osttransplant non-hodgkin lymphoma after kidney transplantation. Transplantation 2010 Mar; 89 (5): 567-72
10. Nourse JP, Jones K, Gandhi MK. Epstein-Barr virus related post-transplant lymphoproliferative disorders:pathogenetic insights into targeted therapy. Am J Transplant 2011; 11: 888-95
11. Boubenider S, Hiesse C, Groupy C, et al. Incidence and consequences of post-transplantation lymphoprolifera-tive disorders. J Nephrol 1997; 10: 136-45 (Pubitemid 27297130)
12. Opelz G, Henderson R. Incidence of non-Hodgkin lym- phoma in kidney and heart transplant recipients. Lancet 1993; 342(8886-7): 1514-6 (Pubitemid 23362168)
13. Younes BS, McDiarmid SV, Martin MG, et al. The effect of immunosuppression on posttransplant lymphoprolife-rative disease in pediatric liver transplant patients. Transplantation 2000; 70: 94-9 (Pubitemid 30490758)
14. Cao S, Cox KL, Berquist W, et al. Long-term outcomes in pediatric liver recipients: comparison between cyclospirin A and tacrolimus. Pediatr Transplant 1999; 3: 22-6 (Pubitemid 29234288)
15. Taylor AL, Marcus R, Bradley JA. Post-transplant lym- phoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 2005; 56: 155-67 (Pubitemid 41278654)
16. Cockfield SM, Preiksaitis J, Harvey E, et al. Is sequential use of ALG and OKT3 in renal transplants associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder? Transplant Proc 1991; 23: 1106-7
17. Caillard S, Dharnidharka V, Agodoa L, et al. Post- transplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80: 1233-43 (Pubitemid 41746802)
18. Kirk AD, Cherikh WS, Ring M, et al. Dissociation of de- pletional induction and posttransplant lymphoprolifera-tive disease in kidney recipients treated with alemtuzu-mab. Am J Transplant 2007; 7: 2619-25 (Pubitemid 47561615)
19. Kahan BD, Yakupoglu YK, Schoenberg L, et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005; 80: 749-58 (Pubitemid 41443756)
20. Kahan BD, Knight R, Schoenberg L, et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc 2003; 35: 25S-34S (Pubitemid 36547913)
21. Yakupoglu YK, Buell JF, Woodle S, et al. Individualiza- tion of immunosuppressive therapy. III. Sirolimus asso-ciated with a reduced incidence of malignancy. Transplant Proc 2006; 38: 358-61
22. DiNardo CD, Tsai DE. Treatment advances in post- transplant lymphoproliferative disease. Curr Opin He-matol2010; 17: 368-74
23. O'Neill JO, Edwards LB, Taylor DO. Mycophenolate mofetil and risk ofdeveloping malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplan-tation. J Heart Lung Transplant 2006; 25: 1186-91 (Pubitemid 44528284)
24. Robson R, Cecka JM, Opelz G, et al. Prospective registry- based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005; 5: 2954-60 (Pubitemid 43923957)
25. Funch DP, Ko HH, Travasso J, et al. Posttransplant lym- phoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil. Trans-plantation 2005; 80: 1174-80 (Pubitemid 41746793)
26. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney trans-plants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547-57
27. Pascual J. Post-transplant lymphoproliferative disorder: the potential of proliferation signal inhibitors. Nephrol Dial Transplant 2007; 22: 27-35
28. Saueressig MG, Boussaud V, Amrein C, et al. Risk factors for post-transplant lymphoproliferative disease in patients with cystic fibrosis. Clin Transplant 2011; 25: E430-6
29. Parker A, Bowles K, Bradley JA, et al. Diagnosis of post- transplant lymphoproliferative disorders in solid organ transplant recipients: BCSH and BTS guidelines. Br J Hematol2010; 149: 675-92
30. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lympho- proliferative disorders: summary of Society for Hemato-pathology Workshop. Semin Diagn Pathol 1997; 14: 8-14 (Pubitemid 27078881)
31. Gulley ML, Tang W. Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn 2008 Jul; 10 (4): 279-92 (Pubitemid 352022708)
32. Gulley ML, Tang W. Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproli-ferative disorder. Clin Microbiol Rev 2010 Apr; 23 (2): 350-66
33. Tsao L, Hsi ED. The clinicopathologic spectrum of post- transplantation lymphoproliferative disorders. Arch Pathol Lab Med2007Aug; 131 (8): 1209-18 (Pubitemid 47257633)
34. Cesarman E, Chadburn A, Liu YF, et al. BCL-6 gene mu- tations in posttransplantation lymphoproliferative dis-orders predict response to therapy and clinical outcome. Blood 1998; 92: 2294-302 (Pubitemid 28452970)
35. Nelson NP, Nalesnik MA, Bahler DW, et al. Epstein-Barr virus-negative posttransplant lymphoproliferative dis-orders: a distinct entity? Am J Surg Pathol 2000; 24: 375-85 (Pubitemid 30127473)
36. Parker A, Bowles K, Bradley JA, et al. Management of post-transplant lymphoproliferative disorders in solid organ transplant recipients: BCSH and BTS guidelines. Br J Hematol 2010; 149: 693-705
37. Vounes A, Samad N. Utility of mTOR inhibition in he- matologic malignancies. Oncologist 2011; 16 (6): 730-41
38. El-Salem M, Raghunath PN, Marzec M, et al. Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders. Lab Invest 2007 Jan; 87 (1): 29-39 (Pubitemid 44973651)
39. Mathew T, Kreis H, Friend P. Two-year incidence of ma- lignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004 Aug; 18 (4): 446-9 (Pubitemid 39077081)
40. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Ne-phrol 2006 Feb; 17 (2): 581-9
41. McDonald RA, SmithJM, Ho M, etal. IncidenceofPTLD in pediatric renal transplant recipients receiving basilix-imab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008 May; 8 (5): 984-9 (Pubitemid 351537758)
42. Krams SM, Martinez OM. Epstein-Barr virus, rapamycin, and host immune responses. Curr Opin Organ Transplant 2008 Dec; 13 (6): 563-8
43. Iaria G, Anselmo A, De Luca L, et al. Conversion to ra- pamycin immunosuppression for malignancy after kidney transplantation: case reports. Transplant Proc 2007 Jul-Aug; 39 (6): 2036-7 (Pubitemid 47198810)
44. Cullis B, D'Souza R, McCullagh P, et al. Sirolimus-induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis 2006 May; 47 (5): 67-72
45. Boratynska M, Watorek E, Smolska D, et al. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies. Transplant Proc 2007 Nov; 39 (9): 2736-9 (Pubitemid 350088107)
46. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003 Aug; 349 (9): 847-58 (Pubitemid 37025404)
47. Witzig TE, Geyer SM, Ghobrial I, et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005 Aug; 23 (23): 5347-56 (Pubitemid 46206988)
48. Nee R, Hurst FP, Dharnidharka VR, et al. Racial variation in the development ofposttransplant lymphoproliferative disorders after renal transplantation. Transplantation 2011 Jul; 92 (2): 190-5
49. Sampaio MS, Cho YW, Shah T, et al. Association of im- munosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients. Transplantation 2012 Jan; 93 (1): 73-81
50. Braconnier P, Del Marmol V, Broeders N, et al. Combined introduction of anti-IL2 receptor antibodies, mycophe-nolic acid and tacrolimus: effect on malignancies after renal transplantation in a single-centre retrospective co-hort study. Nephrol Dial Transplant 2012 Jun; 27 (6): 2547-53
51. Campbell P, Marcus R. Monoclonal antibody therapy for lymphoma. Blood Rev 2003 Sep; 17 (3): 143-52 (Pubitemid 36876674)
52. Weiner GJ. Rituximab: mechanism of action. Semin He- matol 2010 Apr; 47 (2): 115-23
53. Carbone A, Gloghini A, Dotti G. EBV-associated lympho- proliferative disorders: classification and treatment. Oncologist 2008 May; 13 (5): 577-85 (Pubitemid 351872874)
54. Ohta H, Fukushima N, Ozono K. Pediatric post-transplant lymphoproliferative disorder after cardiac transplanta-tion. Int J Hematol 2009 Sep; 90 (2): 127-36
55. Cook RC, Connors JM, Gascoyne RD, et al. Treatment of post-transplant lymphoproliferative disease with ritux-imab monoclonal antibody after lung transplantation. Lancet 1999 Nov; 354 (9191): 1698-9 (Pubitemid 29533063)
56. Oertel SH, Anagnostopoulos I, Bechstein WO, et al. Treatment ofposttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: a new drug in therapy of patients with posttransplant lymphoprolifera-tive disorder after solid organ transplantation? Trans-plantation 2000 Feb; 69 (3): 430-2 (Pubitemid 30118127)
57. Zilz ND, Olson LJ, McGregor CG. Treatment of post- transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation. J Heart Lung Transplant 2001 Jul; 20 (7): 770-2 (Pubitemid 32633879)
58. Berney T, Delis S, Kato T, et al. AG. Successful treatment of posttransplant lymphoproliferative disease with pro-longed rituximab treatment in intestinal transplant re-cipients. Transplantation 2002 Oct; 74 (7): 1000-6 (Pubitemid 35191251)
59. Pham PT, Wilkinson AH, Gritsch HA, et al. Monotherapy with the anti-CD20 monoclonal antibody rituximab in a kidney transplant recipient with posttransplant lympho-proliferative disease. Transplant Proc 2002 Jun; 34 (4): 1178-81 (Pubitemid 34665310)
60. Milpied N, Vasseur B, Parquet N, et al. Humanized anti- CD20 monoclonal antibody (rituximab) in post transplant B- lymphoproliferative disorder: a retrospective analysis on32patients.AnnOncol2000; 11Suppl. 1: 113-6
61. Ganne V, Siddiqi N, Kamplath B, et al. Humanized anti- CD20 monoclonal antibody (rituximab) treatment for post- transplant lymphoproliferative disorder. Clin Transplant 2003 Oct; 17 (5): 417-22 (Pubitemid 37236113)
62. Heslop HE, Savoldo B, Rooney CM. Cellular therapy of Epstein-Barr-virus- associated post-transplant lympho-proliferative disease. Best Pract Res Clin Haematol 2004 Sep; 17 (3): 401-13 (Pubitemid 39462572)
63. Hirokawa M, Kawabata Y, Fujishima N, et al. Prolonged reactivation of cytomegalovirus infection following suc-cessful rituximab therapy for Epstein-Barr virus-associated posttransplantation lymphoproliferative dis-order. Int J Hematol 2007 Oct; 86 (3): 291-2 (Pubitemid 350085824)
64. Imashuku S, Teramura T, Morimoto A, et al. Prolonged hypogammaglobulinemia following rituximab treatment for post transplant Epstein-Barr virus-associated lymphoproli-ferative disease. Bone Marrow Transplant 2004; 33: 129-30 (Pubitemid 38159719)
65. Irie E, Shirota Y, Suzuki C, et al. Severe hypogammaglobu- linemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. Intl J Hematol 2010 Apr; 91 (3): 501-8
66. Savoldo B, Rooney CM, Quiros-Tejeira RE, et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoprolife-rative disease. Am J Transplant 2005 Mar; 5 (3): 566-72 (Pubitemid 40313349)
67. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety ofrituximab in B-cell post-transplantation lympho-proliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006 Apr; 107 (8): 3053-7
68. Dotti G, Rambaldi A, Fiocchi R, et al. Anti-CD20 anti- body (rituximab) administration in patients with late oc-curring lymphomas after solid organ transplant. Haema-tologica 2001 Jun; 86 (6): 618-23 (Pubitemid 32601105)
69. Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti- CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005 Dec; 5 (12): 2901-6 (Pubitemid 43923950)
70. Choquet S, Oertel S, LeBlond V, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution. Ann Hematol 2007 Aug; 86 (8): 599-607 (Pubitemid 47018478)
71. Coiffier B. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin's lymphoma. Semin Oncol 2002Apr; 29 (2 Suppl. 6): 18-22 (Pubitemid 34594980)
72. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005 Jun; 23 (18): 4117-26 (Pubitemid 46211317)
73. Pfreundschuh M, Ho AD, Cavallin-Stahl E, et al., Mab- Thera International Trial (MInT) Group. Prognostic sig-nificance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lym-phoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the Mab-Thera International Trial Group (MInT) study. Lancet Oncol 2008 May; 9 (5): 435-44
74. Jain AB, Marcos A, Pokharna R, et al. Rituximab (chi- meric anti-CD20 antibody) for posttransplant lympho-proliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Trans-plantation 2005 Dec; 80 (12): 1692-8 (Pubitemid 43053993)
75. Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006 Mar; 6 (3): 569-76 (Pubitemid 43382145)
76. Taylor AL, Bowles KM, Callaghan CJ, et al. Anthracy- cline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative dis-order after solid organ transplantation. Transplantation 2006 Aug; 82 (3): 375-81 (Pubitemid 44223037)
77. Buadi FK, Heyman MR, Gocke CD, et al. Treatment and outcomes of post-transplant lymphoproliferative disease: a single institution study. Am J Hematol 2007 Mar; 82 (3): 208-14 (Pubitemid 46363787)
78. Rodriguez-Abreu D, Filho VB, Zucca E. Peripheral T cell lymphomas unspecified (or not otherwise specified): a re-view. Hematol Oncol 2008; 26: 8-20 (Pubitemid 351453961)
79. Evens AM, David KA, Helenowski I, et al. Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: out-comes and prognostic factors in the modern era. J Clin Oncol 2010 Feb; 28 (6): 1038-46
80. Trappe R, Oertel S, Leblond V, et al. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncol 2012; 13 (2): 196-206
81. Trappe R, Hinrichs C, Appel U, et al. Treatment ofPTLD with rituximab and CHOP reduces the risk of renal graft impairment after reduction ofimmunosuppression. Am J Transplant 2009 Oct; 9 (10): 2331-7
82. Cavaliere R, Petroni G, Lopes MB, et al. Primary central nervous system post-transplantation lymphoproliferative disorder: an International Primary Central Nervous Sys-tem Lymphoma Collaborative Group Report. Cancer 2010 Feb; 116 (4): 863-70
83. Nabors LB, Palmer CA, Julian BA, et al. Isolated central nervous system posttransplant lymphoproliferative dis-order treated with high-dose intravenous methotrexate. Am J Transplant 2009 May; 9 (5): 1243-8
84. Funch DP, Walker AM, Schneider G, et al. Ganciclovir and acyclovir reduce the risk of post-transplant lympho-proliferative disorder in renal transplant recipients. Am J Transplant 2005 Dec; 5 (12): 2894-9000
85. Williams SL, Hartline CB, Kushner NL, et al. In vitro ac- tivities ofbenzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob Agents Chemother 2003 Jul; 47 (7): 2186-92 (Pubitemid 36753570)
86. Mentzer SJ, Fingeroth J, Reilly JJ, et al. Arginine butyrate- induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma. Blood Cells Mol Dis 1998 Jun; 24 (2): 114-23 (Pubitemid 28365731)
87. Perrine SP, Hermine O, Small T, et al. A phase I/II trial of arginine butyrate and ganciclovir in patients with Epstein-Barr-virus-associated lymphoid malignancies. Blood 2007 Mar; 109 (6): 2571-8 (Pubitemid 46425904)
88. Aull MJ, Buell JF, Trofe J, et al. Experience with 274 cardiac transplant recipients with posttransplant lymphoprolifera-tive disorder: a report from the Israel Penn International Transplant Tumor Registry. Transplantation 2004 Dec; 78 (11): 1676-82 (Pubitemid 39648443)
89. Bates WD, Gray DW, Dada MA, et al. Lymphoprolifera- tive disorders in Oxford renal transplant recipients. J Clin Pathol 2003 Jun; 56 (6): 439-46 (Pubitemid 36724212)
90. Reams BD, McAdams HP, Howell DN, et al. Post- transplant lymphoproliferative disorder: incidence, pre-sentation, and response to treatment in lung transplant recipients. Chest 2003 Oct; 124 (4): 1242-9 (Pubitemid 37290032)
91. Dotti G, Fiocchi R, Motta T, et al. Lymphomas occurring late after solid-organ transplantation: influence of treat-ment on the clinical outcome. Transplantation 2002 Oct; 74 (8): 1095-102 (Pubitemid 35216102)
92. Douglas RS, Goldstein SM, Katowitz JA, et al. Orbital presentation of posttransplantation lymphoproliferative disorder: a small case series. Ophthalmology 2002 Dec; 109 (12): 2351-5 (Pubitemid 35417123)
93. Buell JF, Gross TG, Hanaway MJ, et al. Posttransplant lymphoproliferative disorder: significance of central ner- vous system involvement. Transplant Proc 2005 Mar; 37 (2): 954-5 (Pubitemid 40590756)
94. Kwong YL, Lam CC, Chan TM. Post-transplantation lymphoproliferative disease ofnatural killer cell lineage: a clinicopathological and molecular analysis. Br J Haematol 2000Jul; 110(1): 197-202 (Pubitemid 30625608)
95. Kwong YL. Natural killer-cell malignancies: diagnosis and treatment. Leukemia 2005 Dec; 19 (12): 2186-94
96. Hsi ED, Singleton TP, Swinnen L, et al. S. Mucosa- associated lymphoid tissue-type lymphomas occurring in post-transplantation patients. Am J Surg Pathol 2000 Jan; 24 (1): 100-6 (Pubitemid 30033402)
97. Aull MJ, Buell JF, Peddi VR, et al. MALToma: Helico- bacter pylori-associated malignancy in transplant patients: a report from the Israel Penn International Transplant Tumor Registry with a review of published literature. Transplantation 2003 Jan; 75 (2): 225-8 (Pubitemid 36139677)
98. Kang SK, Kirkpatrick JP, Halperin EC Low-dose radia- tion for posttransplant lymphoproliferative disorder. Am J Clin Oncol 2003 Apr; 26 (2): 210-4 (Pubitemid 36443570)
99. Comoli P, Maccario R, Locatelli F, et al. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am J Transplant 2005; 5: 1415-22 (Pubitemid 40839433)
100. Comoli P, Labirio M, Basso S, et al. Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence ofactive virus replication. Blood 2002 Apr; 99 (7): 2592-8 (Pubitemid 34525450)
101. Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood 2006 Nov; 108 (9): 2942-9
102. Haque T, Wilkie GM, Taylor C, et al. Treatment of Epstein-Barr-virus- positive post-transplantation lympho- proliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 2002Aug; 360 (9331): 436-42 (Pubitemid 34880139)
103. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cyto- toxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multi-center clinical trial. Blood 2007 Aug; 110 (4): 1123-31 (Pubitemid 47281407)
104. Jones K, Nourse JP, Morrison L, et al. Expansion of EBNA1-specific effector T cells in posttransplantation lymphoproliferative disorders. Blood 2010 Sep; 116 (13): 2245-52
105. Jenkins D, DiFrancesco L, Chaudhry A, et al. Successful treatment ofpost-transplant lymphoproliferative disorder in autologous blood stem cell transplant recipients. Bone Marrow Transplant 2002 Sep; 30 (5): 321-6
106. Ouyang J, Juszczynski P, Rodig SJ, et al. Viral induction and targeted inhibition of galectin-1 in EBV+ post-transplant lymphoproliferative disorders. Blood 2011 Apr; 117 (16): 4315-22
107. Haddad E, Paczesny S, Leblond V, et al. Treatment of B- lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood 2001 Mar; 97 (6): 1590-7 (Pubitemid 32217222)
108. Gu SY, Huang TM, Ruan L, et al. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand 1995; 84: 171-7
109. Posfay-Barbe KM, Siegrist CA. Immunization and trans- plantation: what is new and what is coming? Pediatr Transplant 2009 Jun; 13 (4): 404-10